SALEM, Mass. — Commonwealth Diagnostics International (CDI) is excited to announce that we are now in-network with Regence, a not-for-profit health plan and Blue Cross Blue Shield affiliate.
This new partnership includes Regence BlueShield (Washington), Regence BlueCross BlueShield of Utah, Regence BlueCross BlueShield of Oregon, Regence BlueShield of Idaho, and Asuris Northwest Health, as well as Regence Medicare Advantage plans.
“Through this network expansion, CDI’s industry-leading hydrogen and methane breath tests for SIBO, IMO, and carbohydrate malabsorption will now be more accessible to over 2.4 million members across Washington, Oregon, Idaho, and Utah,” said Craig Strasnick, President & CEO of CDI.
Strengthening CDI’s Presence in the Pacific Northwest & Intermountain Region
With the addition of Regence to CDI’s growing in-network portfolio, CDI continues to expand access to affordable, high-quality diagnostic solutions across the Pacific Northwest and Intermountain Region.
Strasnick continued, “This builds on our recent in-network partnerships with Premera Blue Cross and Medica, furthering our commitment to improving accessibility and affordability for patients in these key regions.”
CDI also remains in-network with Medicare, Medicare Advantage, Tricare, and the VA Community Care Network (CCN), ensuring even broader coverage for patients needing reliable, non-invasive breath testing solutions for functional GI disorders.
A Commitment to Expanding Access
By prioritizing in-network agreements with leading health plans, CDI is making it easier for providers to offer patients cost-effective, clinically validated breath testing without financial barriers. Our best-in-class provider and patient support services and industry-leading turnaround times also provide a seamless diagnostic experience.
To learn more about CDI’s growing list of in-network payers and how our breath testing solutions can support GI practice nationwide, visit commdx.com/insurance.
About Commonwealth Diagnostics International, Inc. (CDI):
Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose familiar sources of digestive distress and functional GI ailments for adults and pediatric patients. Focused on their patient-centric principles, their cost-effective portfolio of diagnostic products results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Their expansive portfolio includes non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methane Overgrowth (IMO), and carbohydrate malabsorption disorders, as well as technology solutions, including MyGI Gateway, a cutting-edge provider portal for enhanced patient care, and MyGI Health, a cloud-based platform that enables patients to monitor, manage and understand their GI-related symptoms. CDI manufactures its clinically validated, FDA-registered and CE marked breath test kits according to ISO 13485 standards and perform all diagnostics in our state-of-the-art, CLIA-certified lab utilizing proprietary diagnostic technologies. For more information, visit commdx.com.
